Copertina

Letter: Why Assessment of ChILI Severity Accurately Matters?

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Mar Riveiro‐Barciela, Guruprasad P. Aithal
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Refining Mortality Estimates in Severe Alcohol‐Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment
di: Shupeng Zhao, et al.
Pubblicazione: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective‐prospective study
di: Elena Vargas‐Accarino, et al.
Pubblicazione: (2024)

Letter: Steroid Tapering in Ulcerative Colitis: The Importance of Disease Severity and Maintenance Therapy
di: Rónán O'Connor, et al.
Pubblicazione: (2026)

Letter: ‘Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study’
di: Matthias Kelm, et al.
Pubblicazione: (2025)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
di: A. B. Fons, et al.
Pubblicazione: (2026)

Baseline HDV ‐ RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study
di: Adriana Palom, et al.
Pubblicazione: (2026)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis
di: Ganesh Bhat, et al.
Pubblicazione: (2026)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
di: Nathan Grellier, et al.
Pubblicazione: (2025)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis. Authors' Reply
di: Amol N. Patil, et al.
Pubblicazione: (2026)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease
di: Chang Liu, et al.
Pubblicazione: (2026)

Letter: Dose and Donor Matter—Determining the Optimal Strategy for Faecal Microbiota Transplantation in Clostridioides difficile Infection. Authors' Reply
di: Sara Ellegaard Paaske, et al.
Pubblicazione: (2026)

An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury
di: Mar Riveiro‐Barciela, et al.
Pubblicazione: (2024)

Letter: Addressing opioid exposure and associated harms in patients with IBD
di: Christian P. Selinger, et al.
Pubblicazione: (2024)

Letter : Is Short Tapering of Steroids in Moderate to Severely Active Ulcerative Colitis Really Inferior to a Long Steroid Taper, or Just Underpowered to Reach a Definitive Conclusion?
di: Hariti Saluja, et al.
Pubblicazione: (2026)

Letter: Post‐HCV Cure, Precision Assessment of Liver Stiffness and Diabetes Risk in Maternal Populations—A Critical Research Need
di: Zihe Guan, et al.
Pubblicazione: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
di: J. M. Schattenberg, et al.
Pubblicazione: (2026)

Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply
di: Jessica A. Fitzpatrick, et al.
Pubblicazione: (2024)

Letter: Irritable bowel syndrome and antibiotics
di: George F. Longstreth
Pubblicazione: (2024)

Letter: Intestinal Ultrasound‐Prioritising Progress
di: Kacie H. Denton, et al.
Pubblicazione: (2026)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
di: Sai Kiran Kuchana, et al.
Pubblicazione: (2026)

Letter: Resmetirom for treatment of MASH with children and adolescents
di: Yong‐Hai Zhou, et al.
Pubblicazione: (2024)

Letter: Steroid Tapering—Is Shorter Duration Better?
di: Juntao Lu, et al.
Pubblicazione: (2026)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
di: Isabel Carbery, et al.
Pubblicazione: (2024)

Letter: Balancing Cost and Consequence of Colon Capsule Endoscopy in Colorectal Cancer Pathways—Finding the Sweet Spot
di: Ian Io Lei, et al.
Pubblicazione: (2025)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
di: Kyle Staller, et al.
Pubblicazione: (2024)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy
di: Mustafa Mohamedrashed, et al.
Pubblicazione: (2024)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
di: Tamar Schildkraut, et al.
Pubblicazione: (2024)

Letter on ‘Telemetric Assessment and Comparison of Regional Colonic Metabolic Activity in Ambulant Healthy Individuals Using pH and Gas‐Sensing Wireless Motility Capsules’: Authors' Reply
di: Phoebe A. Thwaites, et al.
Pubblicazione: (2025)

Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis
di: Richard Pollok
Pubblicazione: (2025)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition?
di: Fernanda Cristofori, et al.
Pubblicazione: (2025)

Letter: Toward Intra‐Class Switching With JAK Inhibitors?
di: Mathieu Uzzan, et al.
Pubblicazione: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations
di: Christophe Corpechot
Pubblicazione: (2026)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis
di: Ewan Forrest, et al.
Pubblicazione: (2025)

Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply
di: María José García, et al.
Pubblicazione: (2024)

Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study
di: Pinelopi Arvaniti, et al.
Pubblicazione: (2025)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
di: Jiamei Wang, et al.
Pubblicazione: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
di: Mingsi Zhang, et al.
Pubblicazione: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
di: Yaomin Wang, et al.
Pubblicazione: (2024)